Top

Published in:

01-08-2007 | Original Research Article

Telithromycin Use and Spontaneous Reports of Hepatotoxicity

Authors: Dr David D. Dore, Julia R. DiBello, Kate L. Lapane

Published in: Drug Safety | Issue 8/2007

Abstract

Background and objective: Recent reports have described cases of telithromycin-related hepatotoxicity. The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity.

Methods: We conducted a spontaneous-report case-control study of hepatotoxicity in telithromycin recipients using reports from the US FDA Adverse Event Reporting System. Reports from between 1 January 2005 and 30 June 2005 were examined. Cases included reports of patients with abnormal liver function tests, hepatocellular damage and hepatic impairment, while patients with reported conditions with similar reporting probabilities were considered as controls. The primary outcome measure of the analysis was the reporting odds ratio (ROR) evaluating the a priori hypothesis that telithromycin use confers an elevated risk of hepatotoxicity relative to other agents.

Results: A total of 2219 cases and 20 667 controls were identified. We estimated an ROR for hepatotoxicity associated with telithromycin compared with other agents of 1.82 (95% CI 1.12, 2.96) after controlling for age and gender, approximating an 82% excess risk in users of telithromycin relative to users of other agents.

Conclusions: This analysis is the first to specifically quantify the effect of telithromycin on the risk of hepatotoxicity. Telithromycin use may increase the risk of hepatotoxicity by >80%. Biases inherent in spontaneous reports include under-reporting of events and differential or time-varying reporting due to enhanced clinician awareness. Future studies should employ alternative data sources because of the inherent limitations of passive surveillance systems.

Ketek (telithromycin) [product information]. Kansas City (MO): Aventis Pharmaceuticals, Inc., 2006 Jun

File TM. Telithromycin new product overview. J Allergy Clin Immunol 2005 Feb; 115(2): 361–70CrossRef

US Food and Drug Administration. FDA completes safety assessment of Ketek new safety information to be added to product labeling, 2006 [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01401.html [Accessed 2006 Jul 10]

Clay KD, Hanson JS, Pope SD, et al. Brief Communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006 Mar; 144(6): 415–20PubMed

Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994; 33(3): 387–401PubMedCrossRef

Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004 Aug; 13(8): 519–23PubMedCrossRef

Tellier G, Brunton SA, Nusrat R. Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent. South Med J 2005 Sep; 98(9): 863–7PubMedCrossRef

Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003; 17: 369–77PubMed

Ferguson BL, Guzzetta RV, Spector S, et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 131(3): 207–14PubMedCrossRef

10.

Fogarty C, de Wet R, Mandell L, et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005 Oct; 128(4): 1980–8PubMedCrossRef

11.

Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002; 30(6): 378–86PubMedCrossRef

12.

Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006 Apr; 354(15): 1589–600PubMedCrossRef

13.

Luterman M, Tellier G, Lasko B, et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003 Aug; 82(8): 576–590PubMed

14.

Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004; 26(1): 48–62PubMedCrossRef

15.

Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004 Aug; 54(2): 515–23PubMedCrossRef

16.

Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999 Feb; 20(2): 109–17PubMedCrossRef

17.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 Apr; 22(4): 719–48PubMed

18.

Pringle E [IMS Health]. Scoop Independent News. Lawmakers demand answers about Ketek from FDA, 2006 [online]. Available from URL: http://www.scoop.co.nz/stories/HL0606/S00279.htm [Accessed 2006 Jul 10]

19.

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 Dec; 137(12): 947–54PubMed

20.

Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005 Dec; 3(12): 1260–8PubMedCrossRef

21.

Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend 2004 Jun; 74(3): 223–34PubMedCrossRef

22.

Moore AA, Gould R, Reuben DB, et al. Longitudinal patterns and predictors of alcohol consumption in the United States. Am J Public Health 2005 Mar; 95(3): 458–65PubMedCrossRef

23.

Cox ER, Frisse M, Behm A, et al. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004 Jun; 164(11): 1243–6PubMedCrossRef

24.

Rehm J, Room R, Graham K, et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 2003 Sep; 98(9): 1209–28PubMedCrossRef

25.

Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001 Aug; 286(7): 831–3PubMedCrossRef

26.

Smalley WD, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000 Dec; 284(23): 3036–9PubMedCrossRef

27.

Mazor KM, Andrade SE, Auger J, et al. Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf 2005 Dec; 14(12): 869–75PubMedCrossRef

28.

Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20 Suppl. C: 40–4CrossRef

Title: Telithromycin Use and Spontaneous Reports of Hepatotoxicity
Authors: Dr David D. Dore
Julia R. DiBello
Kate L. Lapane
Publication date: 01-08-2007
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 8/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200730080-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Telithromycin Use and Spontaneous Reports of Hepatotoxicity

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2007

Drug-Induced Endocrine and Metabolic Disorders

Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation

Allergic Reactions to Medicines Derived from Pelargonium Species

The Authors’ Reply

Physician Response to Patient Reports of Adverse Drug Effects

Safety Profile of Meropenem